Does Mirtazapine Affect Sex Drive? What the Studies Actually Show

Mirtazapine and sex drive usually come up in the same breath with good news: among antidepressants it sits with the ones with the fewest reported sexual side effects. In a 1,022-person prospective study, 24.4% of people on mirtazapine reported a sexual problem, against 57.7% to 72.7% on several SSRIs. The catch is that "fewest" is not "none." Some people on mirtazapine do lose desire, and the price tag that comes with it is sedation, appetite and weight gain. The switch studies are small and open-label, so read them as a hint. They promise nothing.

Is it the mirtazapine, or is it me?

Most people land on this page from one of two directions. You are on mirtazapine for depression, anxiety or sleep, you noticed your desire flatlining, and you want to know whether the tablet is doing it. Or you are on an SSRI, you already suspect it, and you are quietly weighing a switch. This page goes one drug deep so you can walk into your next appointment with a question and leave the hunch at home.

Both groups deserve the same plain answer: your numbers and your mood scales can look perfectly fine while your desire is nowhere to be found, and that gap is not in your head. If you are on an SSRI, start with our guide to SSRIs and libido. The wider picture is in antidepressants and low libido.

Where mirtazapine sits among antidepressants

The clearest head-to-head picture comes from a prospective multicenter study of 1,022 outpatients who had normal sexual function before starting treatment. Interviewers asked directly about libido, the finishing phase, erection function and general satisfaction. Across all the drugs in the study, 59.1% reported a sexual problem. Split by drug, mirtazapine landed at 24.4% (12 of 49 people), while fluoxetine came in at 57.7%, sertraline at 62.9%, paroxetine at 70.7% and citalopram at 72.7%.

Read the margins before you trust them. The study was open-label, with no control group, and the answers came from self-report interviews. The mirtazapine arm was 49 people. That is enough to show a pattern and too few to close the argument.

A meta-analysis that pooled only studies asking about sexual problems with specific questionnaires put mirtazapine in the group with no significant difference from placebo, alongside agomelatine, amineptine, bupropion, moclobemide and nefazodone. The full drug-by-drug ranking is charted on our Wellbutrin page.

Other settings are less flattering. In a cross-sectional study across 1,101 U.S. primary care clinics, bupropion immediate release (22%) and sustained release (25%) and nefazodone (28%) carried the lowest rates, while SSRIs, mirtazapine and venlafaxine extended release all sat in a band of 36% to 43%. Physicians in that study consistently underestimated how common these problems were. A smaller survey in Oman, 137 people on four drugs, found sexual problems in 39% overall, with paroxetine the most common offender; mirtazapine was the lowest of the four.

Figures from Montejo et al. 2001 (PMID 11229449), Watanabe et al. 2010 (PMID 20030418) and Gelenberg et al. 2000 (PMID 10847310).

What the trials and registers count

The pooled evidence points the same way from two directions. A meta-analysis of safety reporting across 25 randomized trials found mirtazapine significantly less likely than SSRIs to cause sexual problems, at a risk ratio of 0.34. The Cochrane review of 29 trials and 4,974 people reached the same conclusion: mirtazapine was less likely than SSRIs to cause nausea, vomiting and sexual problems, and more likely to cause weight gain, increased appetite and drowsiness. That review printed no figure for the sexual comparison, so it gives a direction and no size.

The registers point the same way. In a Danish register study covering 67,721 new mirtazapine treatment episodes in men, mirtazapine carried a modestly lower risk of a recorded sexual problem than citalopram (hazard ratio 0.87, 95% CI 0.81 to 0.93), and that pattern held across analyses. A Swedish study of 169,430 adults found SSRIs linked to higher odds within one year of a depression diagnosis (1.36, 95% CI 1.15 to 1.61) and SNRIs higher still (1.75, 95% CI 1.40 to 2.18), while mirtazapine showed no significant association. Sexual problems get recorded rarely, especially in women, so a register mostly measures what clinicians write down.

A pharmacovigilance study of reports to the World Health Organization's global safety database found the same shape from a third angle. Sexual problems as a category were reported disproportionately often with SSRIs and SNRIs, while agents including mirtazapine showed a lower association. Spontaneous reports are noisy by nature, and a reporting odds ratio is not an incidence rate.

Three sources, three methods, one direction. It is also worth saying what none of them measure: desire itself. A register counts a clinician's note, a safety database counts a submitted report, and a trial counts events that met a reporting rule.

Switching to mirtazapine: what the small studies show

The switch evidence is the part people want, and it is the thinnest part of the page. In one open-label study, 19 people whose sexual problems were linked to an SSRI switched to mirtazapine at doses of 7.5 to 45 milligrams a day for up to six weeks. Eleven of them (58%) reported a return to normal sexual functioning, and 2 more (11%) improved. Their antidepressant response held. The most common side effects were initial sedation, irritability and muscle soreness. Nineteen people is a small room, there was no comparison group, and six weeks is long enough to notice a change and too short to prove one.

A Hungarian prospective study followed 102 outpatients on mirtazapine. Reported sexual problems fell from 93.2% at screening to 61% at one month, 27.1% at three months and 24.6% by the end of the study. That curve lines up nicely with the switch studies. Both are observational, both have no control group, and in both the depression scores improved over the same weeks. A person whose mood lifts usually wants sex more, so you cannot cleanly separate the drug from the recovery.

The one randomized test went the other way. In a placebo-controlled trial in pre-menopausal women with sexual problems that began on fluoxetine, mirtazapine added to the SSRI was inferior to placebo on a structured-interview sexual satisfaction item, and no drug in the trial was consistently better than placebo. The trial ran out of a research lab at a company that makes antidepressants.

Honest summary: the switch studies are open-label, short and tiny, and the only blinded comparison found nothing. That is a reason to treat the switch as a conversation with your prescriber. Nobody should make it alone at midnight. If sedation is the part of mirtazapine you are trying to trade away, the trazodone page covers the other sedating antidepressant people land on.

The trade: sleep, appetite and weight

Mirtazapine's sexual profile is not free. In the same 25-trial pool, drowsiness came in at a risk ratio of 1.62 against SSRIs, fatigue at 1.45, and weight gain or increased appetite at 3.68. About 70% of people on mirtazapine had at least one adverse event, which is no worse than other antidepressants, but the events that show up are the ones people notice.

The sedation is the part most people feel first, and for some it is the point. In a trial in Korean veterans with posttraumatic stress disorder, people took a mean of 34.1 milligrams of mirtazapine a day against 101.5 milligrams of sertraline, and response at week 6 favored mirtazapine, 88% against 69%. Depression scores fell in both groups with no significant difference between them. If you are the person whose sleep has been wrecked for months, that drowsiness is doing a job.

The same trial lists the price: drowsiness in 15.7% of the mirtazapine group, dry mouth and constipation at 19.6% each, and weight gain at 1.96%. The sertraline arm reported sexual problems at 2.0%, and no mirtazapine figure for sexual problems was printed at all.

The weight numbers deserve their own look. A review of published controlled trials on long-term side effects put the gain from most antidepressants at 3 to 4 kilograms after 6 to 12 months, with mirtazapine the exception: it is linked to significant weight gain early in treatment. That review also offers one practical note, and it is the honest close to this page: antidepressant-related sexual problems are common and manageable, with an added agent or a substitution.

So the trade is real, and it is personal. Sedation, appetite and a few kilograms on one side, a lower chance of a flat libido on the other. For some people that is an easy choice. For others the weight lands harder than the desire, and a drug that keeps you sharp in bed and dull everywhere else is not the win it sounds like.

Two pages are worth reading before you choose. Sleep, libido and testosterone explains how sleep and desire feed each other. If your labs came back clean while your desire stayed flat, you are not imagining it; numbers fine, still flat covers that feeling.

Study by study, in order

Mirtazapine (Remeron) has a reputation as the antidepressant that leaves your sex life alone. Six studies sit behind that reputation, and they differ enormously in size and in strength. A switch study followed 19 people with no comparison group. A multicenter survey interviewed 1,022 outpatients. A meta-analysis pooled 25 trials. A pharmacovigilance study read the global safety reports. A register cohort counted 67,721 mirtazapine treatment episodes in Danish men. Small studies exaggerate, and a number recorded by a clinician is a different animal from one you report yourself. In order, with the limits attached:

Mirtazapine in the studies: what each measured and found.

Study	Design	Who	Mirtazapine finding	Comparison
Montejo 2001	Prospective, open-label	1,022 outpatients	Sexual problems in 24.4% (12 of 49)	SSRIs ran 57.7% to 72.7%
Watanabe 2010	Meta-analysis of 25 trials	People in depression trials	Sexual problems risk ratio 0.34 against SSRIs; weight gain and appetite up	Appetite figure 3.68 against the SSRI arms
Gelenberg 2000	Open-label switch	19 people with SSRI-linked problems	11 (58%) back to normal functioning in 6 weeks	No control group at all
Michelson 2002	Randomized, placebo-controlled	36 women on fluoxetine	No advantage over placebo; placebo scored better on one satisfaction item	Placebo arm included
Westphal 2026	Register cohort, men only	67,721 mirtazapine episodes	Hazard ratio 0.87 (95% CI 0.81 to 0.93)	Against citalopram; counts only problems a clinician recorded
Clayton 2002	Cross-sectional survey	6,297 people in primary care	Grouped in the 36% to 43% band with the SSRIs	Bupropion sat lowest at 22% to 25%

What actually helps, graded honestly

Four moves are on the table. They are ranked here by how much evidence stands behind each one, starting with the move you are most likely weighing.

Switch to mirtazapine. This is the move with a direct study attached. In 2000, Gelenberg and colleagues switched 19 people whose sexual problems had started on an SSRI. After 6 weeks on mirtazapine, 11 of them reported normal sexual functioning again, and all 19 kept their antidepressant response. The design is open-label with no comparison group, so the desire returning could belong to mirtazapine, or to the depression lifting over those same 6 weeks. Nineteen people is a small room.

Add mirtazapine on top. This one has the strongest design behind it and the flattest result. Michelson and colleagues ran a randomized trial in women on fluoxetine, giving half an augmentation plan and half a placebo for 6 weeks. The mirtazapine group showed no advantage over placebo, and placebo scored better on one satisfaction item. That is the only test with a placebo arm in this corner of the literature, so the add-it-on-top idea has very little standing behind it.

Change the dose, or change the drug. A 2026 scoping review lists lowering the dose, switching to a lower risk agent, and adding bupropion or an erection drug as the standard moves. This is where the drugs people usually switch from live. The Lexapro page covers escitalopram, and the Zoloft page covers sertraline, the two names that come up most often.

Say it out loud. In a survey across 1,101 primary care clinics, physicians consistently underestimated how common these problems were. Your prescriber probably has not asked because nobody answers. Bring it up first.

Does it wear off on its own?

Sometimes, partially. A 2016 review of newer antidepressants says several side effects are transient and fade after a few weeks, while others persist or show up later, and it lists sexual problems among that second group, noting that at times they can persist after the drug is stopped.

The Hungarian cohort tracked 102 people on mirtazapine. Reported sexual problems fell from 93.2% at screening to 24.6% by the end of the study, and mood scores lifted over the same visits. The study has no control group, so the two curves travel together and nothing separates them.

Nobody has followed desire on mirtazapine against a placebo over time. Treat any improvement as a good sign, keep taking the prescription, and keep telling your doctor what you notice week to week.

What to bring to your prescriber

This conversation goes better with evidence in hand. Bring specifics about your own body, plus the honest size of the studies behind each option. What belongs on the table:

1. The timeline. What changed, and when. Name the week the medication started and the week desire dropped.
2. The depression in the room. Depression pushes on desire in both directions, so your mood belongs in the picture alongside the drug.
3. Which problem it is. Say the words out loud: desire, or trouble finishing. Each one points somewhere different.
4. How common it is. Physicians consistently underestimate these problems, so this item is yours to raise.
5. Sleep and appetite. Mirtazapine trades sedation and weight gain against the rest of what it does. Ask about that trade by name.
6. The size of the switch evidence. Nineteen people, open-label, over 6 weeks. Worth saying out loud in the room.
7. The supplement question. Bring the bottle. Your prescriber can read a label in ten seconds.

The everyday levers, and where a botanical fits

This section is not for everybody. If you take blood-pressure medication, or you have a heart or kidney condition, you are exactly who the NUUD label warns about, so read the caution below and take it to your prescriber. The label says: "avoid use if you are on blood pressure medication, have cardiovascular, renal, or pulmonary conditions, or if you are sensitive to any of the ingredients".

For everyone else, a few ordinary things move desire, and they do their work before any supplement enters the picture.

• Sleep, in quantity and in quality. Sleep and libido covers that link.
• Movement you can keep up. Exercise and libido covers the wider picture.
• The depression itself, treated as the first lever, since it pulls at appetite and mood at the same time.
• Time with a partner with nothing expected at the end.
• A botanical supplement, sitting at the bottom of this list.

If you want that last item, NUUD is a botanical supplement built around desire in general. The formula is anchored by the NUUD Mushroom Complex™, with Muira Puama, Boiled Rehmannia Root, Tribulus Terrestris, and Piper Nigrum for absorption, on a timeline of roughly 30 to 60 minutes. It does nothing for depression, and nothing about mirtazapine or any other antidepressant. The label caution quoted above applies to you before it applies to anybody else. If your prescriber has read that label and has no objection, that is what our women's libido gummies are for. There is a men's version.

Nothing is wrong with you

Two answers are useless here. The first is the shrug, the one that says antidepressants do not touch sex life. In 2001, 24.4% of the people on mirtazapine in a study of 1,022 outpatients reported sexual problems, and a primary-care survey later grouped mirtazapine with the SSRIs in the 36% to 43% band.

The second is the confident internet answer that mirtazapine has no sexual side effects at all. A meta-analysis that asked about sexual problems directly put mirtazapine in the group with no significant difference from placebo, and a Swedish cohort found no significant association for it, which is reassuring. It is also a group average sitting on top of your own body.

Where the numbers land: fewer reports than the SSRIs, with problems still possible, and a switch that helped 11 of 19 people in one small open-label study. Depression flattens wanting by itself. A drug can flatten it further. Life does its own flattening on top.

If you are lying awake wanting to want it again, chasing the day you feel normal again, that is a real target, and it is worth naming out loud at your next appointment.

Keep reading

• Antidepressants and low libido
• SSRIs and the libido drop: what helps
• Does Wellbutrin affect sex drive?
• Does trazodone affect sex drive?
• Does Effexor affect sex drive?
• Why is my libido so low?

Frequently asked questions

Does mirtazapine lower sex drive?
It can, and for some people it does. In a 2001 study of 1,022 outpatients, 24.4% of those on mirtazapine reported sexual problems, which is 12 of 49 people, against 57.7% to 72.7% on the SSRIs. A 2002 survey across 1,101 primary care clinics grouped mirtazapine with the SSRIs in a band running 36% to 43%. So the rate is lower than the SSRI rates in the same study, and it is present for some people.

Does mirtazapine cause fewer sexual side effects than SSRIs?
In most of the studies that compared the two, yes. A 2010 meta-analysis of 25 trials found sexual problems reported far less often on mirtazapine than on SSRIs, with a risk ratio of 0.34. A 2026 Danish register study in men found a hazard ratio of 0.87 against citalopram (95% CI 0.81 to 0.93). A Swedish cohort found no significant association for mirtazapine. These are associations from study reports, and each one counts problems in its own way.

Will switching to mirtazapine fix SSRI sexual side effects?
Sometimes, on weak evidence. In a 2000 open-label switch study, 11 of 19 people reported normal sexual functioning again after 6 weeks on mirtazapine, with the depression lifting over the same period. A randomized trial that added mirtazapine to fluoxetine found no advantage over placebo. So the switch is worth discussing and worth little in the way of a guarantee, and the call belongs to you and your prescriber.

Does mirtazapine increase sex drive?
No trial has shown that. A brain imaging study found that men on mirtazapine showed more activation than men on an SSRI while watching erotic films, which is a measurement of activation. The Hungarian cohorts reported better sex lives as their depression lifted, with no control group attached. Nothing here demonstrates that mirtazapine raises desire in a body that is otherwise doing fine.

Can I take a botanical supplement with mirtazapine?
Ask your prescriber first. No interaction studies exist for this formula, and the label caution covers blood-pressure medication plus heart, kidney and lung conditions. NUUD does nothing for depression, and it has no role in managing any medical condition. Bring the bottle to your appointment and let your prescriber read the label.

References

1. Gelenberg AJ, McGahuey C, Laukes C, et al. Mirtazapine substitution in SSRI-induced sexual dysfunction. The Journal of clinical psychiatry. 2000;61(5):356-60. https://pubmed.ncbi.nlm.nih.gov/10847310/
2. Osváth P, Fekete S, Vörös V, Almási J. Mirtazapine treatment and sexual functions: Results of a Hungarian, multicentre, prospective study in depressed out-patients. International journal of psychiatry in clinical practice. 2007;11(3):242-5. https://pubmed.ncbi.nlm.nih.gov/24941365/
3. Osváth P, Fekete S, Vörös V, Almási J. [Changes in sexual function in mirtazapine treatment. Primary data of a national, multicenter, prospective observational study in depressed patients]. Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakologiai Egyesulet lapja = official journal of the Hungarian Association of Psychopharmacology. 2005;7(4):177-86. https://pubmed.ncbi.nlm.nih.gov/16496482/
4. Michelson D, Kociban K, Tamura R, Morrison MF. Mirtazapine, yohimbine or olanzapine augmentation therapy for serotonin reuptake-associated female sexual dysfunction: a randomized, placebo controlled trial. Journal of psychiatric research. 2002;36(3):147-52. https://pubmed.ncbi.nlm.nih.gov/11886692/
5. Watanabe N, Omori IM, Nakagawa A, et al. Safety reporting and adverse-event profile of mirtazapine described in randomized controlled trials in comparison with other classes of antidepressants in the acute-phase treatment of adults with depression: systematic review and meta-analysis. CNS drugs. 2010;24(1):35-53. https://pubmed.ncbi.nlm.nih.gov/20030418/
6. Zeiss R, Malejko K, Connemann B, Gahr M, Durner V, Graf H. Sexual Dysfunction Induced by Antidepressants-A Pharmacovigilance Study Using Data from VigiBase(TM). Pharmaceuticals (Basel, Switzerland). 2024;17(7):. https://pubmed.ncbi.nlm.nih.gov/39065677/
7. Zini J, Turecki G. Antidepressant-Induced Sexual Dysfunction in Adults: A Targeted Scoping Review and Clinical Update. Journal of clinical psychopharmacology. 2026. https://pubmed.ncbi.nlm.nih.gov/42333401/
8. Kim W, Jin BR, Yang WS, et al. Treatment with selective serotonin reuptake inhibitors and mirtapazine results in differential brain activation by visual erotic stimuli in patients with major depressive disorder. Psychiatry investigation. 2009;6(2):85-95. https://pubmed.ncbi.nlm.nih.gov/20046380/
9. Chung MY, Min KH, Jun YJ, Kim SS, Kim WC, Jun EM. Efficacy and tolerability of mirtazapine and sertraline in Korean veterans with posttraumatic stress disorder: a randomized open label trial. Human psychopharmacology. 2004;19(7):489-94. https://pubmed.ncbi.nlm.nih.gov/15378676/
10. Watanabe N, Omori IM, Nakagawa A, et al. Mirtazapine versus other antidepressive agents for depression. The Cochrane database of systematic reviews. 2011;2011(12):CD006528. https://pubmed.ncbi.nlm.nih.gov/22161405/
11. Serretti A, Chiesa A. Treatment-emergent sexual dysfunction related to antidepressants: a meta-analysis. Journal of clinical psychopharmacology. 2009;29(3):259-66. https://pubmed.ncbi.nlm.nih.gov/19440080/
12. Montejo AL, Llorca G, Izquierdo JA, Rico-Villademoros F. Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicenter study of 1022 outpatients. Spanish Working Group for the Study of Psychotropic-Related Sexual Dysfunction. The Journal of clinical psychiatry. 2001;62 Suppl 3:10-21. https://pubmed.ncbi.nlm.nih.gov/11229449/
13. Clayton AH, Pradko JF, Croft HA, et al. Prevalence of sexual dysfunction among newer antidepressants. The Journal of clinical psychiatry. 2002;63(4):357-66. https://pubmed.ncbi.nlm.nih.gov/12000211/
14. Clayton AH, El Haddad S, Iluonakhamhe JP, Ponce Martinez C, Schuck AE. Sexual dysfunction associated with major depressive disorder and antidepressant treatment. Expert opinion on drug safety. 2014;13(10):1361-74. https://pubmed.ncbi.nlm.nih.gov/25148932/
15. AlBreiki M, AlMaqbali M, AlRisi K, AlSinawi H, Al Zakwani W. Prevalence of antidepressant-induced sexual dysfunction among psychiatric outpatients attending a tertiary care hospital. Neurosciences (Riyadh, Saudi Arabia). 2020;25(1):55-60. https://pubmed.ncbi.nlm.nih.gov/31982896/
16. Rabinowitz MJ, Li O, Pil EH, et al. Antidepressant nonadherence and sexual dysfunction among young adult males: the cross-sectional YAMAN study. World journal of urology. 2024;42(1):295. https://pubmed.ncbi.nlm.nih.gov/38709300/
17. Westphal L, Gräf DD, Le H, Hallgreen CE, Andersen M. Sexual Dysfunction in Male Patients After Initiating Treatment with Antidepressants. Drug safety. 2026;49(4):493-503. https://pubmed.ncbi.nlm.nih.gov/41203969/
18. Isung J, Karlsson P, Tankaya O, Johansson V, Gembert K, Reutfors J. Patterns and treatment of sexual dysfunction in major depressive disorder: A cohort and case-control study in Sweden. Journal of affective disorders. 2026;410:121999. https://pubmed.ncbi.nlm.nih.gov/42167696/
19. Masand PS, Gupta S. Long-term side effects of newer-generation antidepressants: SSRIS, venlafaxine, nefazodone, bupropion, and mirtazapine. Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists. 2002;14(3):175-82. https://pubmed.ncbi.nlm.nih.gov/12585567/
20. Carvalho AF, Sharma MS, Brunoni AR, Vieta E, Fava GA. The Safety, Tolerability and Risks Associated with the Use of Newer Generation Antidepressant Drugs: A Critical Review of the Literature. Psychotherapy and psychosomatics. 2016;85(5):270-88. https://pubmed.ncbi.nlm.nih.gov/27508501/

This article is for general education and is not medical advice. Depression and anxiety are medical conditions that only a licensed clinician can diagnose and manage, as is insomnia, and mirtazapine (Remeron) is a prescription medicine. NUUD is a botanical supplement and has no role in diagnosing, treating, curing, or preventing depression, anxiety, the side effects of any medication, or any other disease, and these statements have not been evaluated by the Food and Drug Administration. Talk with your doctor before starting any new supplement, and do not stop or change your medication without your doctor.